M. Glauser

发表

Anticytokine Therapies in Patients with Severe Sepsis and Septic Shock

T. Calandra, P. Bochud, M. Glauser, 2003 .

The Generation of Inflammatory Responses

T. Calandra, M. Glauser, D. Heumann, 2002 .

Anticytokine strategies for the treatment of septic shock: relevance of animal models.

M. Glauser, D. Heumann, 1996, Current topics in microbiology and immunology.

Contribution of TNF and of LPS in endotoxemic shock in mice. A reappraisal

M. Glauser, D. Heumann, D. Le Roy, 1996 .

Cytokines and septic shock.

T. Calandra, M. Glauser, 1990, Diagnostic microbiology and infectious disease.

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

G. Grau, M. Glauser, D. Heumann, 1990, The Journal of experimental medicine.

Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock

J. Schellekens, T. Calandra, G. Grau, 1990 .

Protection from septic shock by neutralization of macrophage migration inhibitory factor

R. Bucala, T. Calandra, B. Echtenacher, 2000, Nature Medicine.

Septic shock: pathogenesis

M. Glauser, J. Cohen, J. Baumgartner, 1991, The Lancet.

Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin

T. Calandra, M. Glauser, D. Heumann, 2001, Infection and Immunity.

against Gram-Negative Bacteria Protein and CD14 in Immune Responses Critical Role of Lipopolysaccharide-Binding

T. Calandra, F. Padova, M. Glauser, 2001 .

Gram-Negative Bacteria Protein and CD 14 in Immune Responses Critical Role of Lipopolysaccharide-Binding

T. Calandra, F. Padova, M. Glauser, 2001 .

Critical Role of Lipopolysaccharide-Binding Protein and CD14 in Immune Responses against Gram-Negative Bacteria1

T. Calandra, F. D. Di Padova, M. Glauser, 2001, The Journal of Immunology.

Molecular basis of host-pathogen interaction in septic shock.

T. Calandra, M. Glauser, D. Heumann, 1998, Current opinion in microbiology.

Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria

T. Calandra, T. Roger, M. Glauser, 2001, Journal of endotoxin research.

Treatment options of invasive fungal infections in adults.

D. Pittet, T. Calandra, M. Glauser, 2006, Swiss medical weekly.

Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group.

J. Schellekens, T. Calandra, G. Grau, 1990, The Journal of infectious diseases.

Gram-Negative Bacteria Protein and CD 14 in Immune Responses Critical Role of Lipopolysaccharide-Binding

T. Calandra, F. Padova, M. Glauser, 2001 .

Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide.

P. Abbet, M. Glauser, D. Heumann, 1992, Journal of immunology.

Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes.

R. Ulevitch, M. Glauser, D. Heumann, 1992, Journal of immunology.

Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock.

M. Glauser, D. Heumann, D. Le Roy, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

M. Glauser, D. Heumann, D. Le Roy, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Reactivity of murine and human recombinant LPS-binding protein (LBP) within LPS and gram negative bacteria.

C. Jongeneel, R. Ulevitch, V. Kravchenko, 1995, Journal of inflammation.

LBP or the Presentation of LPS / LBP by Blocking Either the Binding of LPS to ( LBP ) Protect Mice from Lethal Endotoxemia Lipopolysaccharide ( LPS )-Binding Protein Monoclonal Antibodies to Murine

R. Landmann, T. Calandra, F. Padova, 1999 .

CD14 is a pattern recognition receptor.

A. Tomasz, R. Ulevitch, V. Kravchenko, 1994, Immunity.

Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock.

R. Landmann, T. Calandra, M. Glauser, 1995, The Journal of infectious diseases.

Northern and in Situ Hybridizations Protein Interaction and Nf-kb Reporter Assays

T. Calandra, T. Roger, J. David, 2022 .

Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.

D. Pittet, T. Calandra, M. Glauser, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock

J. Carlet, T. Calandra, P. Bochud, 2002 .

Septic shock: treatment

M. Glauser, J. Cohen, Jonathan Cohen, 1991, The Lancet.

Périard et al Lipids , Lp ( a ) , HIV , and Protease Inhibitors

A. Telenti, V. Mooser, P. Halfon, 1999 .

Immunoprophylaxis and Immunotherapy of Gram-negative Bacterial Infections

M. Glauser, J. Baumgartner, 1994 .

Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes

A. Tomasz, M. Glauser, D. Heumann, 1994, Infection and immunity.

Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS.

T. Calandra, M. Glauser, D. Heumann, 1994, The Journal of infectious diseases.

Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient.

M. Glauser, J. Baumgartner, 1987, Reviews of infectious diseases.

CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumonia.

M. Schaller, R. Chioléro, T. Calandra, 2001, Swiss medical weekly.

Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14.

R. Landmann, T. Calandra, F. D. Di Padova, 1999, Journal of immunology.

LPS binding protein (LBP) function in germfree mice

M. Glauser, D. Heumann, D. Le Roy, 1997 .

Shock: An Update

M. Glauser, D. Heumann, D. Baumgartner, 2010 .

Immunotherapy of Gram-negative Septic Shock

M. Glauser, J. Baumgartner, 1990 .

Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock

J. Schellekens, T. Calandra, M. Glauser, 1989, Thrombosis and Haemostasis.

The Inflammatory Cytokines

M. Glauser, 2012, Drugs.

Do monoclonal antibodies and anticytokines still have a future in infectious diseases?

M. Glauser, D. Heumann, J. Cohen, 1995, The American journal of medicine.

Immunotherapy of endotoxemia and septicemia.

M. Glauser, J. Baumgartner, 1993, Immunobiology.

Macrophage migration inhibitory factor and innate immune responses to bacterial infections

T. Calandra, T. Roger, M. Glauser, 2001, Critical care medicine.

Short time exposure to lipopolysaccharide is sufficient to activate human monocytes.

C. Jongeneel, M. Glauser, D. Heumann, 1993, Journal of immunology.

Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma.

R. Landmann, M. Glauser, D. Heumann, 1994, Journal of immunological methods.

Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide.

M. Glauser, D. Heumann, P. Gallay, 1994, The Journal of infectious diseases.

Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes.

M. Glauser, D. Heumann, P. Gallay, 1993, The Journal of infectious diseases.

Purification and characterization of murine lipopolysaccharide-binding protein

R. Ulevitch, M. Glauser, D. Heumann, 1993, Infection and immunity.

Neutropenia: clinical implications and modulation

M. Glauser, 2000, Intensive Care Medicine.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

H. Bruining, T. Butler, K. Kudsk, 1997, JAMA.

Streptococcus mitis cell walls and lipopolysaccharide induce lethality in D-galactosamine-sensitized mice by a tumor necrosis factor-dependent pathway

G. Grau, M. Glauser, D. Heumann, 1996, Infection and immunity.

Contribution of TNF/TNF receptor and of Fas ligand to toxicity in murine models of endotoxemia and bacterial peritonitis.

J. Tschopp, B. Ryffel, M. Hahne, 1995, Journal of inflammation.

Task Force: Guidelines for the problem of sepsis (ESICM)

J. Vincent, J. Rello, J. Takala, 1994 .

Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.

T. Calandra, M. Glauser, D. Heumann, 1991, Journal of Infectious Diseases.

PREVENTING DEATH FROM SHOCK BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID

W. Knaus, R. Freeman, J. McCutchan, 1985, The Lancet.

Antibiotics in sepsis

T. Calandra, P. Bochud, M. Glauser, 2001, Intensive Care Medicine.

118 TREATMENT OF SEVERE INFECTIOUS PURPURA IN CHILDREN WILL HUMAN PLASMA FROM DONORS IMMUNIZED WITH ESCHERICHILA COLI JS: A PROSPECTIVE, DOUBLE BLIND STUDY

S. Suter, E. Girardin, G. Grau, 1991, Pediatric Research.

Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation

Charles J. Fisher, Michael A. Matthay, S. Opal, 2000, Critical care medicine.

Pathogenesis and potential strategies for prevention and treatment of septic shock: an update.

Jonathan Cohen, M. Glauser, D. Heumann, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

T. Calandra, M. Glauser, D. Heumann, 1991, The American journal of medicine.

Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

J. Schellekens, T. Calandra, M. Glauser, 1988, The Journal of infectious diseases.

Comparative study of imipenem in severe infections.

M. Glauser, J. Baumgartner, 1983, The Journal of antimicrobial chemotherapy.

MIF regulates innate immune responses through modulation of Toll-like receptor 4

T. Calandra, T. Roger, J. David, 2001, Nature.

An attempt to demonstrate cell-mediated reactivity to penicillin. Using a direct heterologous modification of the macrophages migration inhibition test.

M. Glauser, G. Perruisseau, P. Frei, 1973, International archives of allergy and applied immunology.

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

S M Marcovina, A. Telenti, V. Mooser, 1999, Circulation.

Single Daily Dose Treatment of Severe Refractory Infections With Ceftriaxone: Cost Savings and Possible Parenteral Outpatient Treatment

M. Glauser, J. Baumgartner, 1983 .

Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.

M. Glauser, J. Baumgartner, 1983, Archives of internal medicine.

Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists

D. Pittet, T. Calandra, M. Glauser, 2005, Intensive Care Medicine.

Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.

M. Glauser, D. Heumann, J. Baumgartner, 1991, The Journal of infectious diseases.

Immunotherapy and Immunoprophylaxis of Sepsis

M. Glauser, J. Baumgartner, 1989 .

Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.

M. Glauser, J. Baumgartner, T. Kirkland, 1987, The Journal of infectious diseases.

Immunotherapy of Life-threatening Gram-negative Infections: Facts and Controversies

M. Glauser, J. Baumgartner, 1987 .

Interpretation of data regarding the protection afforded by serum, IgG, or IgM antibodies after immunization with the rough mutant R595 of Salmonella minnesota.

M. Glauser, J. Baumgartner, M. M. Wu, 1989, The Journal of infectious diseases.

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection.

Martin L. Lee, M. Glauser, J. Baumgartner, 1992, The New England journal of medicine.

PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID

J. McCutchan, R. Chioléro, M. Klauber, 1985, The Lancet.

Treatment of gram-negative bacteremia in patients with cancer and granulocytopenia.

E. Anaissie, T. Calandra, M. Glauser, 1988, The New England journal of medicine.

Anti-endotoxin immunotherapy in septic shock.

M. Glauser, J. Baumgartner, 1987, The Journal of antimicrobial chemotherapy.

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group.

S. Suter, E. Girardin, G. Grau, 1992, The Journal of infectious diseases.

p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial

H. Bruining, T. Butler, K. Kudsk, 1997 .

Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia.

R. Chioléro, B. Yersin, C. Jaccard, 1997, Critical care medicine.

Evolution of plasminogen activator inhibitor type 1 in patients with septic shock — correlation with cytokine concentrations

T. Calandra, M. Glauser, D. Heumann, 1993 .

Digestion of Streptococcus pneumoniae Cell Walls with Its Major Peptidoglycan Hydrolase Releases Branched Stem Peptides Carrying Proinflammatory Activity*

H. Langen, M. Fountoulakis, M. Glauser, 1999, The Journal of Biological Chemistry.

The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock.

M. Glauser, 1996, Drugs.

Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy

P. Schnyder, G. Pantaleo, F. Miedema, 1998, Nature Medicine.

The HA-1A monoclonal antibody for gram-negative sepsis.

C. Sprung, C. Mecher, H. Feldman, 1991, The New England journal of medicine.

Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia.

M. Glauser, J. Baumgartner, 1984, The American journal of medicine.

IFN-gamma involvement in the severity of gram-negative infections in mice.

D. Leroy, M. Glauser, D. Heumann, 1993, Journal of immunology.

NITRIC OXIDE PRODUCTION IN EXPERIMENTAL GRAM-NEGATIVE INFECTION: STUDIES WITH CYTOKINE RECEPTOR-DEFICIENT MICE

M. Glauser, D. Heumann, D. Le Roy, 1998, Shock.

International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee.

M. Glauser, L. Thijs, R. Finch, 1996, Critical care medicine.

Pharmacokinetic and microbial susceptibility studies of ceftriaxone

M. Glauser, J. Baumgartner, 1983, European Journal of Clinical Microbiology.

Immunocompromised animal models for the study of antibiotic combinations.

T. Calandra, M. Glauser, 1986, The American journal of medicine.

From the bench to the bedside: The future of sepsis research - Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop

S. Hurd, D. Teres, G. Bernard, 1997 .

Pathophysiologic basis of sepsis: Considerations for future strategies of intervention

M. Glauser, 2000, Critical care medicine.

F. D. Di Padova, E. Rietschel, M. Glauser, 1997, Infection and immunity.

Monocyte deactivation in septic shock.

T. Calandra, M. Glauser, D. Heumann, 1998, Current opinion in infectious diseases.

Comparative imipenem treatment of Staphylococcus aureus endocarditis in the rat.

M. Glauser, J. Baumgartner, 1983, The Journal of antimicrobial chemotherapy.

Tumor necrosis factor

R. Bone, R. Wenzel, M. Glauser, 1993 .

Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein.

T. Vischer, M. Glauser, D. Heumann, 1995, The Journal of rheumatology.

Lipopolysaccharide binding protein (LBP) as a marker of protein leakage in cerebrospinal fluid

H. Albrecht, M. Glauser, D. Heumann, 1995 .

Therapeutic Approaches Targeting Endotoxin-Derived Mediators

M. Glauser, D. Heumann, J. Baumgartner, 2020 .

Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.

T. Calandra, M. Glauser, J. Baumgartner, 1991, Progress in clinical and biological research.

Failure of dexamethasone to prevent polymorphonuclear leukocyte infiltration during experimental acute exudative pyelonephritis and to reduce subsequent chronic scarring.

P. Meylan, M. Glauser, M. Glauser, 1988, The Journal of infectious diseases.

S. Hurd, D. Teres, G. Bernard, 1997 .